Overview
- 1 public-safe observation is available for this inspection.
- 1 structured CFR citation is represented.
- 4 investigators are tied to this Form 483.
Inspectional observations
Each observation cites the regulation FDA found the firm out of compliance with.
18 Mar 2016
21 CFR 58.35(b)(5)
QAU: authorize deviations from protocols or SOPs
Cited by Mark J Seaton, Marcelo O Mangalindan, Ching-Jey G Chang, Tahseen Mirza
Inspected site
GLGlaxoSmithKline LLCKing Of Prussia, United States
Inspection team
Cited regulations
CFR citations associated with this Form 483.
| Citation | What it covers | Cited |
|---|---|---|
| 21 CFR 58.35(b)(5) | Cited across public-safe Form 483 observations | 1x |
Source document
PDF
PDF available
Form 483 source document
The source document is available to authorized Atlas users.
Full 483 report
Get the verbatim text of all 1 observation
The source PDF, so your team sees exactly what was cited and how it was answered.
- The site's full inspection history around this Form 483
- Whether these citations escalated to a warning letter
- The investigators involved and the citations they repeat elsewhere